Premium
Evaluation of low dose continuous infusion 5‐fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group study
Author(s) -
Kish Julie A.,
Wolf Michael,
David Crawford E.,
Leimert Joseph T.,
Bueschen Anton,
Neefe John R.,
Flanigan Robert C.
Publication year - 1994
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19940801)74:3<916::aid-cncr2820740319>3.0.co;2-z
Subject(s) - medicine , fluorouracil , renal cell carcinoma , oncology , continuous infusion , carcinoma , urology , chemotherapy
Background . The response rate of metastatic renal cell cancer to cytotoxic therapy over the last 10 years has been 5.6%. Low dose continuous 5‐fluorouracil (5‐FU) has demonstrated efficacy in other cytotoxic refractory tumors, such as pancreas, colorectal, and recurrent breast. The Southwest Oncology Group undertook a Phase II trial of low dose, continuous 5‐FU in metastatic renal cell cancer. Methods . Sixty‐one patients were entered in the study to receive 300 mg 5‐FU/m 2 /day for 7 days via a central venous catheter and external programmable pump. The pump was refilled every 7 days. Pyridoxine (50 mg, orally) was administered prophylactically three times a day. Results . A response of 5.2% (one complete response [CR] and two partial responses [PRs]) was achieved. The overall survival was 12 months. The duration of the CR is more than 30 months. Both PRs lasted 6 months. No survival advantage was noted with either prior nephrectomy or biologic therapy. The majority of toxicities were Grade 2: anemia, anorexia, diarrhea, nausea/vomiting, and stomatitis. No toxic deaths occurred. Conclusion . Low dose, continuous 5‐FU demonstrated minimal activity in metastatic renal cancer.